{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:27:19Z","timestamp":1783441639337,"version":"3.54.6"},"reference-count":13,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medical Case Reports"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p> Vitiligo is a common, autoimmune, depigmenting disorder of the skin. Janus Kinase inhibitors have emerged as promising topical and oral therapeutic options for vitiligo. There have been no reports of vitiligo being treated with oral Abrocitinib, a selective Janus Kinase 1 inhibitor approved for the treatment of moderate to severe atopic dermatitis. Here, we present a 61-year-old male with acrofacial vitiligo who had repigmentation plateau with twice daily tacrolimus 0.1% ointment, oral ginkgo biloba, and oral minipulse prednisone \u00d7 4 months; however, they had significant improvement after taking abrocitinib 100 mg per day for 2 months. He was able to transition topical tacrolimus twice weekly monotherapy for maintenance. This report shows that oral Janus Kinase inhibitors may be a useful option for the treatment of recalcitrant vitiligo. Results of ongoing randomized control trials are needed to determine the durability and safety of oral Janus Kinase inhibitors long-term. <\/jats:p>","DOI":"10.1177\/2050313x241231527","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T12:10:41Z","timestamp":1707912641000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: A case report"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-9606","authenticated-orcid":false,"given":"Seyyon","family":"Satkunanathan","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1891-0438","authenticated-orcid":false,"given":"Mina","family":"Boshra","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis","family":"Chang","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetesh","family":"Bose","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"Division of Dermatology, Department of Medicine, University of Ottawa and The Ottawa Hospital, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"bibr1-2050313X241231527","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-081X(97)00125-9"},{"key":"bibr2-2050313X241231527","doi-asserted-by":"publisher","DOI":"10.1159\/000506103"},{"key":"bibr3-2050313X241231527","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.061"},{"key":"bibr4-2050313X241231527","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00631-6"},{"key":"bibr5-2050313X241231527","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419833609"},{"key":"bibr6-2050313X241231527","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125"},{"key":"bibr7-2050313X241231527","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02847"},{"key":"bibr8-2050313X241231527","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1735615"},{"key":"bibr9-2050313X241231527","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735"},{"key":"bibr10-2050313X241231527","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0880-2"},{"key":"bibr11-2050313X241231527","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20198086"},{"key":"bibr12-2050313X241231527","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13348"},{"key":"bibr13-2050313X241231527","unstructured":"University Hospital, Bordeaux. Evaluation of Effect and Tolerance of the Association of Baricitinib (4 Mg) and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized, Double-Blind, Prospective, Non-Comparative Phase II Study. clinicaltrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT04822584 (2023, accessed 31 December 2022)."}],"container-title":["SAGE Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X241231527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X241231527","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X241231527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T11:21:47Z","timestamp":1740828107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X241231527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":13,"alternative-id":["10.1177\/2050313X241231527"],"URL":"https:\/\/doi.org\/10.1177\/2050313x241231527","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"2050313X241231527"}}